Tumor protein D52 (TPD52) (TPD52)

Tumor protein D52 (TPD52) mRNA encodes a protein that is a member of the TPD52 family, characterized by a highly conserved coiled-coil domain. This target is significantly overexpressed in various human cancers, including breast, prostate, and ovarian malignancies, where it acts as an oncogene by promoting cell proliferation and survival (UniProt P55327; PMID: 23833040). TPD52 is involved in essential cellular processes such as vesicle trafficking and calcium-mediated signal transduction, which are often hijacked in cancer cells to support rapid growth (NCBI Gene ID: 7163). As a therapeutic target, TPD52 mRNA is primarily addressed through RNA interference (RNAi) strategies, such as small interfering RNAs (siRNAs), which aim to reduce the levels of the TPD52 protein (PMID: 15150102). Experimental studies have demonstrated that knocking down TPD52 mRNA leads to decreased cell viability and increased apoptosis in cancer cell lines, making it a promising candidate for targeted gene therapy. Despite its potential, challenges remain regarding the efficient delivery of RNA-based drugs and the management of potential off-target effects in non-cancerous tissues.

Other names

D52hD52N8LPC-1PrLZTumor protein D52

RNA interference (RNAi) or antisense-mediated degradation of mRNA leading to reduced protein expression and subsequent inhibition of cell proliferation and induction of apoptosis.